Prognostic Value of Circulating Tumor DNA-Based Minimal Residual Disease for Recurrence-Free Survival in Resectable Gastric Cancer: A Systematic Review and Meta-Analysis with Serial Monitoring Analysis
Digestive Diseases and Sciences · 2026
DOI: 10.1007/s10620-026-10014-8 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Abdul Ahad Mehboob und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Christie NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Circulating Tumor DNA, Stomach Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) is an emerging biomarker, but its utility in resectable gastric cancer remains incompletely characterized. METHODS: We conducted a systematic review and meta-analysis of eight studies (520 patients) to evaluate the prognostic value of ctDNA-based MRD for recurrence-free survival (RFS) and overall survival (OS) in resectable gastric cancer. RESULTS: In localized resectable gastric cancer (Stage I-III), the setting in which postoperative ctDNA most coherently represents true molecular residual disease after curative-intent surgery, postoperative ctDNA positivity was associated with diminished recurrence-free survival (RFS: HR 12.26, 95% CI 3.30-45.52) and overall survival (OS: HR 8.57, 95% CI 3.06-23.98). The test for subgroup differences between localized and mixed-stage cohorts was not statistically significant (P = 0.57), and the numerically higher HR in the localized subgroup should therefore not be interpreted as evidence of a quantitatively stronger prognostic effect. Postoperative ctDNA detection demonstrated substantially stronger prognostic value (overall RFS: HR 10.00, 95% CI 4.53-22.10) compared to preoperative assessment (HR 2.17, 95% CI 1.10-4.28). Both tumor-informed and tumor-agnostic strategies effectively stratified high-risk patients. However, these effect sizes should be interpreted cautiously given the small number of studies and substantial heterogeneity (I2 = 65-72%). Results from mixed-stage cohorts including Stage IV disease are supportive but should not be considered equivalent to localized-disease findings, as ctDNA in metastatic disease reflects persistent systemic burden rather than minimal residual disease in the postoperative sense. CONCLUSIONS: Postoperative ctDNA-based MRD shows a consistent adverse prognostic association in resectable gastric cancer, with localized disease (Stage I-III) representing the most biologically and clinically coherent setting for interpretation. However, the large pooled hazard ratios (HR 10.00-12.26) should be interpreted as a directionally consistent signal rather than precise quantitative estimates, given the small number of studies, wide confidence intervals, and substantial heterogeneity (I2 = 65-73%). This heterogeneity is largely driven by substantial variation in postoperative sampling timing (4 days to 16 weeks) and ctDNA assay characteristics (platform, sensitivity, coverage, variant filtering, and positivity thresholds), which require standardization in future studies. While ctDNA is prognostically valuable, its clinical utility remains unestablished. Prospective randomized trials are needed to determine whether ctDNA-guided strategies improve patient outcomes before routine clinical implementation can be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Christie NHS Foundation Trust, Manchester, UK.
- Department of Medicine, Nash General Hospital, Rocky Mount, NC, USA.
- Department of Internal Medicine, United Medical and Dental College, Karachi, Pakistan.
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy. attaullah.khan@unicampania.it.
- Department of Basic Medical Sciences, College of Medicine, Majmaah University, 11952, Al Majmaah, Saudi Arabia.
Zitieren
APA
Mehboob, A. A., Iqbal, A. G., Butt, T. S., Khan, A. U., & Kazmi, S. Y. (2026). Prognostic Value of Circulating Tumor DNA-Based Minimal Residual Disease for Recurrence-Free Survival in Resectable Gastric Cancer: A Systematic Review and Meta-Analysis with Serial Monitoring Analysis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-10014-8
Vancouver
Mehboob AA, Iqbal AG, Butt TS, Khan AU, Kazmi SY. Prognostic Value of Circulating Tumor DNA-Based Minimal Residual Disease for Recurrence-Free Survival in Resectable Gastric Cancer: A Systematic Review and Meta-Analysis with Serial Monitoring Analysis. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-10014-8
BibTeX
@article{Mehboob2026,
author = {Mehboob, Abdul Ahad and Iqbal, Abdul Ghani and Butt, Tooba Shaukat and Khan, Atta Ullah and Kazmi, Syed Yousaf},
title = {Prognostic Value of Circulating Tumor DNA-Based Minimal Residual Disease for Recurrence-Free Survival in Resectable Gastric Cancer: A Systematic Review and Meta-Analysis with Serial Monitoring Analysis},
journal = {Digestive Diseases and Sciences},
year = {2026},
doi = {10.1007/s10620-026-10014-8}
}
EUVIMED